Basal Cell Carcinoma Market: Overview
Basal cell carcinoma (BCC), which is also known as basal cell epithelioma is one of the most prevalent and common forms of skin cancers worldwide. BCC mainly arises from the basal cells, which are small cells that are round in shape and are located within the lower layer of the epidermis. These types of cancers can easily be identified, but if ignored it can cause several consequences with significant morbidity.
Basal cell carcinoma mostly affects head area including the scalp, face, neck, and hands. It’s characteristic features include waxy papules with central depression, pearly appearance, ulceration, bleeding if traumatized, crusted structures, and translucency, among others. For most of the cancer cases, these types of cancers have been observed that they do not metastasize or spread to other parts of the body.
However, they can invade the surrounding tissues by growing and hence causing damage to other neighboring tissues or organs of the body. Presently, basal cell carcinoma can be treated via different techniques, such as, radiotherapy, chemotherapy etc. that are being utilized for the treatment of several types of tumors or cancers. However, several manufacturers across geographies are studying different basal cell carcinomas and developing therapeutic drugs that are in different stages of their clinical trials, which will soon hit the global market.
Basal Cell Carcinoma Market: Key Growth Enablers
Major driving factors for the growth of this market include increasing prevalence of several skin cancers, global warming, rapidly depleting ozone layer, rising demand advanced therapeutics, and increasing awareness about several available treatment options. The increasing prevalence of several skin cancers, especially basal cell carcinoma, which accounts for most of the skin cancers worldwide, will continually provide growth towards this market.
According to the World Health Organization’s estimates in 2012, each year around 2 million to 3 million people suffer from these non-melanoma cancers worldwide. Global warming along with the depleting ozone layer will cause more incoming of harmful solar ultraviolet radiations into the earth’s atmosphere, which will further increase the number of skin cancer patients worldwide. According to the WHO estimates in 2012, around 300,000 patients will be added each year to the above estimates if the ozone layer is depleted by decreasing ozone levels by 10%. Also, increasing demand for advanced therapeutics, rising number of therapeutic drugs in several phases of clinical trials will continue to provide boost towards the growth of this market in future.
Basal Cell Carcinoma Market: Region-wise Insight
Geographically, North America and Europe are expected to dominate the basal cell carcinoma market in the near future. Major factors responsible for their dominance in this market include high prevalence of BCC in those regions, high demand for advanced therapeutics and high purchasing power of the population of those regions. However, emerging economies of Asia-Pacific, LATAM and the Middle East regions are also expected to show a rapid growth in this market. Major factors responsible for their rapid growth in near future would be the increasing awareness and demand for advanced therapeutics in these economies, rising medical tourism in these regions and increasing affordability of the people of these regions.
Some of the major players operating or having their therapeutic drugs in clinical trials, include, 4SC AG, Berg Pharma, LLC, Bristol-Myers Squibb Company, Cannabis Science, Inc., Curis, Inc., F. Hoffmann-La Roche Ltd., Galderma S.A., Graceway Pharmaceuticals, LLC, MediGene AG, Meda AB, Novartis AG, Peplin, Inc., and Oncovir, Inc.
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Basal Cell Carcinoma Market during 2016- 2024
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453